

Non-Clinical Development of an Antibody-Drug Conjugate (ADC) Targeting RTK-like Receptors for the Treatment of Solid Tumors

Aimed Bio Inc



ONCOLOGY	Preclinical
Product Type	Antibody
Indication	Lung cancer, Breast cancer, Ovarian cancer
Target	Undisclosed
MoA(Mechanism of Action)	<p>Target Binding – The antibody part binds specifically to the target antigen on the tumor cell surface.</p> <p>Internalization – The ADC-antigen complex is internalized into the cell by endocytosis.</p> <p>Payload Release – The linker is cleaved inside the cell, releasing the cytotoxic drug.</p> <p>Cell Killing – The released payload induces DNA damage leading to cancer cell death.</p>
Competitiveness	<p>Best-in-Class, ADC</p> <ul style="list-style-type: none"> - Superior cellular internalization and target degradation with high affinity - Composed of a novel antibody and novel payload - Demonstrates superior anti-tumor efficacy in solid tumors compared to the most clinically advanced competitor ADC.
Development Stage	Preclinical
Route of Administration	Intravenous (IV)

Any unauthorized distribution or reproduction of this material is strictly prohibited.